THE APPLICATION OF STATINS IN THE PREVENTION OF PRIMARY AND SECONDARY CEREBRAL INFARCTION AND TRANSIENT ISCHEMIC ATTACKS (literature review)
https://doi.org/10.51523/2708-6011.2013-10-4-4
Abstract
The application of statins in cardiology aimed at reduction of the risk of cardiovascular problems has noticeably increased over the last years. In this regard, it has been assumed that statins can be effective in the primary and secondary prevention of cerebral infarction and transient ischemic attack. The recent studies have provided contradictory data on the issue, which reduces the assignability of this group of drugs by neurologists. This review covers the characteristic features of statins in angioneurology.
About the Authors
N. V. Galinovskaya
Gomel State Medical University
Belarus
Belarus
N. N. Usova
Gomel State Medical University
Belarus
Belarus
V. Ya. Latysheva
Gomel State Medical University
Belarus
Belarus
References
1. Guidelines for the Early Management of Stroke Patients / C. Edward [et al.] // Stroke. - 2013. - Vol. 44. - P. 870-947.
2. Болезни нервной системы: руководство для врачей: в 2 т. / под ред. Н. Н. Яхно, Д. Р. Штульмана. - М.: Медицина, 2001. - Т. 1. - С. 253-256.
3. Лихачев, С. А. Транзиторные ишемические атаки: этиология, патогенез, классификация, клиника, диагностика / С. А. Лихачев, А. В. Астапенко, Н. Н. Белявский // Мед. новости. - 2003. - № 10. - С. 31-37.
4. Kanntl, W. B. Risk factors in coronary beast disease. An evaluation of several lipids as predictors of coronary heart disease; the Framingbam study / W. B. Kanntl // Ann. Intenn. Med. - 1964. - Vol. 61. - P. 88-89.
5. Epidemiologic studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries / A. Keys [et al.] // Acta. Med. Scand. - 1967. - Vol. 460., Suppl. 1 - P. 1-392.
6. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project / M. Gostynski [et al.] // Int. J. Obes. Relat. Metab. Disord. - 2004. - Vol. 28, № 8. - P. 1082-1090.
7. Stamler, J. The Multiple Risk Factor Intervention Trial (MRFIT) - importance then and now / J. Stamler, J. D. Neaton // JAMA. - 2008. - Vol. 300, № 11. - P. 1343-1345.
8. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза: Российские рекомендации, V пересмотр. // Атеросклероз и дислипидемии. - 2012. - № 4. - С. 5-53.
9. Эволюция представлений о про- и антиатерогенных свойствах липопротеинов / В. С. Гуревич [и др.] // Атеросклероз и дислипидемии. - 2012. - № 4. - С. 55-62.
10. Martens, A. Oxidized LDL and HDL: Antagonists in аtherothrombosis / A. Martens, P. Holvoet // FASEB J. - 2001. - Vol. 15 (12). - P. 2073-2084.
11. Chen, L. G. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase, protein expression in human platelets; relevance of the effect of oxidized LDL on platelet function / L. G. Chen, P. Mehta, I. L. Mehta // Curculation. - 1996. - Vol. 93 (9). - P. 1740-1746.
12. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells. Relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction / L. Li [et al.] // Circ. Res. - 2004. - Vol. 95, № 9. - P. 877-884.
13. Денисенко, А. Д. Модифицированные липопротеины и атеросклероз / Атеросклероз. Проблемы патогенеза и терапии / А. Д. Денисенко; под ред. А. Н. Климова, Е. В. Шляхто. - СПб.: Мед. лит., 2006. - С. 13-33.
14. Berglund, L. Lipoprotein(a): an elusive cardiovascular risk factor / L. Berglund, R. Ramakrishnan // Artherioscler. Thromb. Vasc. Biol. - 2004. - Vol. 24, № 12. - P. 2219-2226.
15. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin / S. N. Sotiriou [et al.] // FASEB J. - 2006. - Vol. 20, № 3. - P. 559-561.
16. ESC/EAS Guidelines for management of dyslipidaemias // Atherosclerosis. - 2011. - Vol. 217S. - P. 1-44.
17. Schaefer, J. R. HDL level or HDL function as the primary target in preventive cardiology / J. R. Schaefer // Herz. - 2012. - Vol. 37, № 5. - P. 51-55.
18. Климов, А. Н. Взаимодействие липопротеидов высокой плотности и их подфракций с интимой аорты человека, пораженной атеросклерозом / А. Н. Климов, Л. Г. Петрова-Маслакова // Вопр. мед. химии. - 1982. - Т. 28, № 2. - С. 122-125.
19. Cromwell, W. C. High dencity lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result? / W. C. Cromwell // J. Clin. Lipidol. - 2007. - Vol. 1, № 1. - P. 57-64.
20. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL / M. Navab [et al.] // J. Lipid. Res. - 2004. - Vol. 45, № 6. - P. 993-1007.
21. Podrez, E. A. Anti-oxidant properties of high-density lipoprotein and atherosclerosis / E. A. Podrez // Clin. Exp. Pharmacol. Phyiol. - 2010. - Vol. 37, № 7. - P. 719-725.
22. Kontush, A. Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis / A. Kontush, M. J. Chapman // Pharmacological Reviews. - 2006. - Vol. 58, № 3. - P. 342-374.
23. Cholesterol Level and Stroke / J. Willey [at al.] // JAMA Intern Med. - 2013. - Vol. 173 (19). - P. 1765-1766.
24. Amarenco, P. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention / P. Amarenco, J. Labreuche // Lancet Neurol. - 2009. - Vol. 8. - P. 453-463.
25. Amarenco, P. The paradox of cholesterol and stroke / P. Amarenco, P. G. Steg // Lancet. - 2007. - Vol. 370. - P. 1803-1804.
26. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths // Lancet. - 2007. - Vol. 370. - P. 1829-1839.
27. Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack / P. Amarenco [at al.] // New England Journal of Medicine. 2006. - Vol. 355. - P. 549-559.
28. Профиль липидного спектра у пациентов с ишемическим повреждением головного мозга / В. Б. Смычек [и др.] // Неврол. и нейрохирург. Восточная Европа. - 2013. - № 2 (18). - С. 122-131.
29. Сывороточный холестерин как прогностический показатель при тяжелой ожоговой травме / Т. А. Ушакова [и др.] // Клиническая и лабораторная диагностика. - 2010. - № 9. - С. 54.
30. Творогова, М. Г. Липиды и липопротеины. Лабораторная диагностика нарушений липидтранспортной системы (лекция) / М. Г. Творогова // Клиническая и лабораторная диагностика. - 2008. - № 10. - С. 29-32.
31. Васильева, Е. М. Биохимические изменения при неврологической патологии / Е. М. Васильева, М. И. Баканов // Биомед. химия. - 2005. - Т. 51(6). - С. 581-602.
32. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review / E. M. Balk [et al.] // Ann. Intern. Med. - 2003. - Vol. 139(8). - Р. 670-682.
33. Furie Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack / L. Furie Karen [at al.] // Stroke. - 2011. - Vol. 42. - P. 227-276.
34. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) / P. H. Jones [et al.] // Am. J. Cardiol. - 2003. - Vol. 92 (2). - P. 152-160.
35. Briasoulis, A. Antihypertensive Effects of Statins: A Meta-Analysis of Prospective Controlled Studies / A. Briasoulis, V. Agarwal, A. Valachis // J. of Clin. Hyp. - Vol. 15 (5). - 2013. - Р. 310-320.
36. Gissi-Hf, I. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. / I. Gissi-Hf, // Lancet. - 2008. - Vol. 372. - P. 1231-1239.
37. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial / R. J. Glynn [еt al.] // Ann. Intern. Med. - 2010. - Vol. 152. - P. 488-496.
38. Rosuvastatin in older patients with systolic heart failure / J. Kjekshus [еt al.]. // N. Engl. J. Med. - 2007. - Vol. 357. - P. 2248-2261.
39. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis / P. Amarenco [еt al.] // Stroke. - 2004. - Vol. 35. - P. 2902-2909.
40. Ovbiagele, B. Statin therapy after stroke or transient ischemic attack: a new weapon in our secondary stroke prevention arsenal? / B. Ovbiagele // Nat. Clin. Pract. Neurol. - 2007. - Vol. 3. - P. 130-131.
41. Amarenco, P Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study / P. Amarenco, J. Bogousslavsky, A. S. Callahan // Cerebrovasc. Dis. - 2003. - Vol. 16. - P. 389-395.
42. Statin treatment withdrawal in ischemic stroke: a controlled randomized study / M. Blanco [еt al.] // Neurology. - 2007. - Vol. 69. - P. 904-910.
43. Reduction in Early Stroke Risk in Carotid Stenosis With Transient Ischemic Attack Associated With Statin Treatment / A. Merwick [et al.] // Stroke. - 2013. - Vol. 44(10). - P. 2814-2820.
44. Инструкции по профилактике инфаркта мозга и транзиторных ишемических атак: приказ от 09.09.2011 г. № 878 / Министерство здравоохранения Республики Беларусь. - Минск, 2011. - 22 с.
45. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial // The Lancet. - Vol. 376 (9753). - P. 1658-1669.
46. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases / R. Colin [et al.] // BMJ. - 2013. - Vol. 346. - P. 880-890.
47. Acute kidney injury in statin initiators / J. B. Layton [et. al.] // Pharmacoepidemiology and Drug Safety. - 2013. - Vol. 22 (10). - P. 1061-1070.
48. The Adverse Events Research Team / J. Leuschen [еt al.] // JAMA Ophthalmol. - 2013. - Vol. 131(11). - P. 1427-1434.
49. Central nervous system and limb anomalies in case reports of first-trimester statin exposure / R. J. Edison, M. Muenke // N. Engl. J. Med. - 2004. - Vol. 350 (15). - P. 1579-1582.
50. Clinical inquiries. What precautions should we use with statins for women of childbearing age? / C. Patel [et al.] // J. Fam. Pract. - 2006. - Vol. 55 (1). - P. 75-77.
Review
For citations:
Galinovskaya N.V., Usova N.N., Latysheva V.Ya. THE APPLICATION OF STATINS IN THE PREVENTION OF PRIMARY AND SECONDARY CEREBRAL INFARCTION AND TRANSIENT ISCHEMIC ATTACKS (literature review). Health and Ecology Issues. 2013;(4):27-33. (In Russ.) https://doi.org/10.51523/2708-6011.2013-10-4-4
Views: 391
Email this article 